Stock Halts Amidst Clinical Milestone Purchase Agreement

Immunome Acquires Antibody-Related Assets from Atreca: A Significant Step Forward in Biotech.

In a significant development, Immunome Inc. (Nasdaq: IMNM), has entered into an asset purchase agreement with Atreca Inc. (Nasdaq: BCEL) to acquire a collection of antibody-related assets and materials. This deal promises to boost Immunome's portfolio and potentially accelerate the development of their immunotherapy programs.

Under the terms of the agree…